Announcement on Abnormal Fluctuations in Stock Trading
Filed with SSE · · 4 pages · Chinese
Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix
Later from Shenzhen Chipscreen Biosciences
- Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell Lymphoma
- Announcement on Voluntary Disclosure of Semi-annual Earnings Preannouncement for 2025
- Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- Announcement on Continuing to Use Temporarily Idle Raised Funds for Cash Management
Follow Shenzhen Chipscreen Biosciences into a list and get an email when it puts out news.
Follow Shenzhen Chipscreen Biosciences